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ABSTRACT 
The putative effects of diabetes and metabolic control on circulat- 
ing levels of insulin-like growth factors (IGFs) and their binding 
proteins (IGFBPs) remain controversial. In the present study, serum 
levels of IGF-I and IGF-II and IGFBP-1, -2, and -3 were measured in 
58 patients (age, 0.8-17 yr) with treated (51 subjects) or untreated (7 
subjects) insulin-dependent diabetes mellitus (IDDM) and were com- 
pared with the levels in normal subjects. In the untreated patients 
IGF-I and IGF-II were decreased as compared with the healthy con- 
trols. In the treated diabetics IGF-I and IGF-II were reduced; 
IGFBP-2 (only in prepubertal subjects) and IGFBP-3 were increased. 
Furthermore, age-adjusted values of IGF-I, IGF-II, and IGFBP-3 
were lower in prepubertal than in pubertal patients. Regression anal- 
ysis revealed a negative correlation between hemoglobin (Hb)Alc and 
standard deviation scores (SDS) of IGF-I and a positive association 
between HbAlc and IGFBP-1 SDS or IGFBP-2 SDS. In the treated 
patients HbAlc was positively related to IGFBP-1 SDS and IGFBP-2 
SDS when applying simple regression analysis and to IGFBP-2 SDS 
when using a multiple regression model. Strong correlations were 
observed between height SDS and IGF-I SDS, IGF-II SDS, and 
IGFBP-3 SDS in prepubertal subjects who had had IDDM for at least 
2 yr, but not in adolescents. Such correlations have also been found 
in healthy children and adolescents. In conclusion; 1) IDDM is asso- 
ciated with alterations of the IGF-IGFBP system, which are partially 
accounted for by differences in metabolic control and pubertal status; 
2) the lower plasma concentrations of serum IGF-I may play a role in 
the pathogenesis of growth impairment of poorly controlled prepu- 
bertal, but not pubertal, children and adolescents with IDDM; and 3) 
in addition, a potential role of the altered IGF-IGFBP system for the 
development of diabetic late complications is hypothesized. (J Clin 
Endocrinol Metab 80: 1207-1213, 1995). 
S HORT- and long-term consequences of insulin-depen- dent diabetes mellitus (IDDM) not only result from 
insulin deficiency itself but also from secondary metabolic 
and hormonal derangements. In the last decade interest has 
focused on insulin-like growth factor-I (IGF-I) as a candidate 
molecule that may play a key role in the pathogenesis of 
immediate or late diabetic complications (l-7). 
IGF-I is a GH-dependent polypeptide that has a S-fold 
function as a mediator of the growth-promoting action of 
GH, as a potent mitogenic factor, and as a metabolic regulator 
with insulin-like activity (1, 7). Alterations of IGF-I regula- 
tion may provide an attractive explanation for IDDM-asso- 
ciated growth impairment as well as for proliferative micro- 
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vascular complications. So far, it is unclear whether IGF-II, 
a peptide that is homologous to IGF-I, could likewise play a 
pathophysiological role in diabetic complications. In viva and 
in vitro studies have suggested mitogenic and metabolic 
functions for IGF-II that are similar to those of IGF-I. In 
addition, IGF-II is thought to be an important regulator of 
fetal and embryonic growth (2,7). It is unclear whether IGF-II 
is GH dependent (1, 2, 7). Unlike IGF-I, the serum concen- 
tration of which increases during childhood and puberty 
secondary to rising GH secretion, in the human IGF-II levels 
remain nearly constant after an initial rise during the first 
year of life (7-9). In the circulation the vast majority of the 
IGFs is bound to specific carrier proteins, the IGF-binding 
proteins (IGFBPs), which greatly prolong their half-time and 
regulate their bioavailability and their bioactivity (3, 4, 10, 
11). So far, six different IGFBPs (IGFBP-1 to -6) have been 
cloned and sequenced. 
The predominant IGFBP in the blood is IGFBP-3, which 
forms a large 150-kilodalton (kDa) ternary complex. The 
serum level of this complex determines the total concentra- 
tion of circulating IGFs and regulates the growth-promoting 
potential of IGF-I (2, 10-19). Serum levels of IGF-I 
and IGFBP-3 are positively related to nutritional status and 
age during childhood and adolescence (20-25). It is not 
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definitively settled, however, whether IGFBP-3 is acutely 
regulated by GH or IGF-I (26-28). Current oppinion favors 
GH as the major regulator of IGFBP-3 levels in the human. 
In viva and in vitro experiments indicate relatively poor con- 
trol of IGFBP-3 concentrations by IGF-I (8, 9, 20, 29-31). 
The second most abundant IGFBP in the circulation is 
IGFBP-2, a 31.3-kDa protein with a preferential affinity for 
IGF-II. Little is known about the regulation and biological 
function of IGFBP-2. In animals insulin may control IGFBP-2 
production (21,23). However, no such regulation was found 
in man (20). 
IGFBP-1, a 25-kDa carrier protein, might play an important 
role in modulating mitogenic and metabolic effects of free 
IGFs. Insulin-like activity is blocked by excess IGFBP-1, 
whereas the mitogenic potential of the IGFs can be enhanced 
or inhibited by IGFBP-1 depending on the target cells and the 
experimental conditions (14-17). Inasmuch as hepatic IG- 
FBI’-1 secretion is directly suppressed by insulin and stim- 
ulated by substrate deprivation (l&19,24-28,32), this carrier 
protein might be directly involved in glucose counterregu- 
lation. IGFBP-1 might inhibit the glucose-lowering potential 
of IGFs in response to hypoglycemia and allow for the ex- 
pression of insulin-like activity after food intake. IGFBP-1 
levels are inversely related to insulin levels in healthy (25,26) 
and in diabetic subjects (27,28). They decline with advancing 
age, coinciding with rising insulin secretion (32, 33). A 
marked circadian variation with peak levels in the early 
morning when insulin levels are lowest has been reported 
(32). 
The close relationship between the IGF-IGFBP system and 
glucose homeostasis has encouraged many investigators to 
study the influence of diabetes on the serum levels of the 
IGFs and/or the IGFBPs. The data from these studies are 
rather conflicting. We have systematically and simulta- 
neously measured serum levels of five components of the 
IGF-IGFBP system in children and adolescents with diabetes. 
Importantly, we have asked whether alterations of the 
IGF-IGFBP system impair growth of diabetic children. 
Subjects and Methods 
Diabetic subjects 
The study population consisted of 58 children and adolescents with 
IDDM, 21 girls and 37 boys. At the time of blood sampling 7 patients had 
not yet received exogenous insulin therapy, since they had just been 
hospitalized with newly detected diabetes; none of them had required 
intensive care hospitalization. The remaining 51 patients had been di- 
abetic for at least 3 months before blood sampling. Insulin therapy was 
conventional (2 daily injections) in 40 and intensified (at least 3 daily 
injections) in 11 subjects. Apart from IDDM, none of the patients had an 
acute or chronic illness. Other than insulin the patients did not receive 
any medication. No hormonal deficiency that could be expected to 
interfere with metabolism of IGFs or IGFBPs was present in any of the 
patients. The patients’ heights, weights, pubertal stages according to 
Tanner, and HbAlc values were recorded at each clinical visit. Hemo- 
globin Ale (HbAlc) was measured by high performance liquid chro- 
matography (Diamat, BioRad, Richmond, CA). Venous blood samples 
for determination of IGFs and IGFBPs were obtained during routine 
visits in the afternoon together with samples for routine blood testing. 
The study protocol was approved by the Ethical Committee of the Chil- 
dren’s Hospital, University of Munich. Parents and patients gave their 
informed consent. 
Control subjects 
The control population consisted of 600 healthy, male and female 
children and adolescents. Serum samples for measurement of the IGFs 
and IGFBPs were collected during daytime. The results were used to 
establish percentiles for each biochemical parameter. Comparisons 
between the patients and the reference subjects were based on age- 
independent standard deviation scores (SDS) (29, 34, 35). 
Biochemical methods 
IGF-I MA. IGF-I was measured by an IGFBP-blocked RIA using a highly 
specific polyclonal antiserum with a cross-reactivity with IGF-II of less 
than 0.05% (a kind gift of Drs. B. Breier and I’. Gluckman, Children’s 
Hospital, University of Auckland, Auckland, New Zealand) (30, 36). 
Briefly, serum samples were diluted 1:150 in an acidic buffer to dissociate 
IGFs from IGFBP. On neutralization, a large excess of IGF-II (Mediag- 
nost, Tubingen, Germany) was added to block IGFBP-binding sites. 
Details of the assay will be published elsewhere. The sensitivity at a 
serum dilution of 1:150 was 3 pg/L, and the intraassay and interassay 
coefficients of variation at 50% B/B, were 3.2% and 7.4%, respectively. 
IGF-II MA. The assay was performed in acid-ethanol extracts using a 
specific antiserum for the Cpeptide domain of IGF-II (29,30,35). Cross- 
reactivitv of the antiserum with IGF-I is less than 0.005%. Interference 
of residual IGFBPs was blocked by addition of excess IGF-I as described 
before (35,36). Intraassay and interassay coefficients of variation at 50% 
B/B, (n = 20) were 3.7 and 9.6%, respectively. 
IGFBP NAs. IGFBP-1 was measured by a specific RIA as described 
previously (30). IGFBP-2 was measured by RIA using a polyclonal an- 
tiserum against a synthetic partial sequence of IGFBP-2 (176-190) as 
described before (22), except that for preparation of radiolabeled tracer 
and of standards, recombinant IGFBP-2 (a kind gift of Sandoz, Basel, 
Switzerland) was used. IGFBP3 was measured by RIA using a specific 
polyclonal antiserum against authentic IGFBP-3 purified from human 
Cohn fraction IV, which showed no cross-reactivity with IGFBP-1 or 
IGFBP-2 up to 1 mg/L. Details of the assay have been reported 
previously (37). 
Statistics 
Results are expressed as mean ? SD, median and range. SDS were 
used if required to remove an obvious or possible age dependence 
(height and serum levels of IGFs and IGFBPs). For calculating height z 
scores the data from the Zurich longitudinal study were used (38). 
Statistical calculations were performgd with the StatWorks program 
(Cricket Software, I’hiladelohia, PA). Differences between groups were 
evaluated by the unpaired t’ test; Simple regression analysis”wasLused to 
assess the relationship between two parameters. Multiple regression 
analysis was performed to determine which variables were indepen- 
dently associated with constants. Two-way analysis of variance was 
applied to both regression analysis models. 
Results 
Clinical results 
Clinical and diabetes characteristics of the study popula- 
tion are presented in Table 1. Actual age, age at onset of 
diabetes and body mass index (BMI) did not differ between 
treated and untreated patients. Height SDS and HbAlc were 
significantly higher in the untreated patients (height SDS, 
0.32 US. 0.53, P < 0.001; HbAlc, 8.1% ZIS. 12.2%, P < 0.0001). 
When the patients on insulin therapy were grouped as pre- 
pubertal (n = 28) and pubertal (n = 23), both groups differed 
significantly with respect to the duration of diabetes 
(P < 0.003) but not with regard to height SDS, age at onset 
of diabetes, and HbAlc. 
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TABLE 1. Clinical and diabetes characteristics of the study 
subjects 
Mean k SD 
Age W 10.9 5 3.9 
SDS height -0.23 2 1.14 
Duration (yr) 4.0 k 3.9 
Age at onset (yr) 6.9 ?I 3.8 
Insulin (U/kg)a 0.75 k 0.22 
HbAlc (%) 8.6 2 2.1 
a Only treated patients (n = 51). 
Median Range 
11.0 0.8-17.5 
-0.17 -2.47-+2.9 
2.9 o-15 
6.6 0.8-14.4 
0.78 0.32-1.23 
8.0 5.2-16.8 
Biochemical results 
Serum levels and SDS of IGF-I, IGF-II, and IGFBP-1, -2, and 
-3 of treated and untreated patients and P values for differ- 
ences between the diabetic patients and the reference pop- 
ulation are presented in Tables 2 and 3. Figure 1 shows the 
graphical distribution of the patients’ data within the cor- 
responding percentiles. In the whole group of treated and 
untreated patients, IGF-I and IGF-II levels were significantly 
reduced (P < 0.001) and serum IGFBP-3 elevated (P < 0.001) 
compared with the reference values. Subjects with untreated 
IDDM had decreased serum concentrations of IGF-I and 
IGF-II (P < 0.01). IGFBP-2 tended to be increased and 
IGFBP3 to be reduced in subjects with untreated IDDM. 
These differences were not significant due to great interin- 
dividual variation. In the group of patients with treated 
IDDM, a marked reduction of IGF-I and IGF-II levels 
(P < 0.001) and an increase of IGFBP-3 levels 0’ < 0.001) was 
evident. Comparison of patients with and without insulin 
therapy revealed lower serum concentrations of IGF-I and 
IGFBP-3 (P < 0.0001) and higher IGFBP-2 levels (P < 0.0001) 
in the untreated diabetics. When the population of treated 
patients was grouped into prepubertal and pubertal, serum 
levels of IGF-I (P < 0.01) and IGFBP-3 (P < 0.03) were lower 
in the prepubertal patients than in the pubertal patients 
(IGF-1 SDS, -0.86 VS. -0.21; IGFBP-3 SDS, 0.84 VS. 1.47). 
Serum concentrations of IGF-I were normal in the pubertal 
patients but reduced (P < 0.001) in the prepubertal patients. 
IGFBP-2 levels were normal in the pubertal patients but 
elevated in prepubertal patients (P < 0.01). Serum IGF-II was 
reduced (P < 0.001) and serum IGFBP-3 increased (P < 0.001) 
both in pubertal and prepubertal patients. 
Possible interrelationships between clinical or diabetes pa- 
rameters (age, BMI, insulin dose, duration of diabetes, age at 
onset, and HbAlc) and the SDS of the IGFs and IGFBPs were 
assessed by simple regression analysis. The analysis was 
applied to the overall study population and also to the group 
of treated patients alone. The results of this analysis are 
presented in Table 4. Figure 2 shows the relationship be- 
tween IGF-I SDS or IGFBP-2 SDS and HbAlc in the overall 
study population; IGFBP-2 and IGFBP-1 levels correlate 
significantly with HbAlc levels, whereas IGF-I is inversely 
related to HbAlc. Multiple regression analysis was per- 
formed to evaluate independence of variables (gender, age, 
BMI, duration of diabetes, and HbAlc). Parameters without 
significant correlations in the simple regression model were 
not included in this analysis. Possible relationships between 
SDS height and the SDS of the IGFs and IGFBPs were eval- 
uated only in those patients who had IDDM for at least 2 yr. 
In this population, simple regression analysis revealed pos- 
itive correlations between height SDS and IGF-I SDS 
(r = 0.47; P < 0.0041, IGF-II SDS (r = 0.43; P < 0.0081, and 
IGFBP-3 SDS (r = 0.53; P < 0.001). Analogous results were 
obtained with multiple regression analysis using gender, 
age, duration of diabetes, and HbAlc as covariables (Table 
5). In the prepubertal subjects, however, height SDS was 
strongly related to IGF-I SDS (F = 4.4; r = 0.76; P < O.OOOl), 
IGF-II SDS (F = 5.3; r = 0.71: P < O.OOOl), and IGFBP-3 SDS 
(F = 5.1; r = 0.8; P < 0.0001). Such correlations were not 
found in pubertal patients. It is important to realize that 
height SDS did not differ significantly between both groups 
of patients (-0.37 in prepubertal VS. -0.13 in pubertal 
patients). 
Discussion 
This study reveals the presence of multiple alterations in 
the IGF and IGFBP system of diabetic children and adoles- 
cents. IGF-I levels were reduced in patients with and without 
insulin therapy. In the literature, data regarding IDDM- 
associated alterations of IGF-I levels are conflicting (5, 
39-46). In adult patients IGF-I has been demonstrated to be 
decreased (33,44,45,47,48), normal (6, 27) or increased (5, 
44). When IGF-I levels in children and adolescents are mea- 
sured, the strong age dependence of IGF-I should be taken 
into account. Of three studies fulfilling this criterion, one 
found decreased serum IGF-I in well controlled patients (43); 
another reported subnormal IGF-I levels in adolescents (42); 
and one found no significant difference of IGF-I levels be- 
tween diabetics and healthy children and adolescents (40). In 
none of the studies were age-adjusted IGF-I values of pre- 
pubertal and pubertal patients compared. As a reason why 
IGF-I levels are normal in our adolescent diabetics but low 
in the prepubertal patients, the following possible explana- 
tions come to mind. The diabetes-associated suppression of 
IGF-I generation is attributed to GH receptor (6,49) or post- 
receptor (45, 46) defects. Although GH is the major deter- 
minant of circulating IGF-I, other factors such as sex steroids 
TABLE 2. Serum levels and SDS of IGF-I, IGF-II, IGFBP-1, IGFBP-2, and IGFBP-3 in 51 treated patients with IDDM 
Sennn levels C&L) SDS 
P 
Mean 2 SD Median Range Mean 2 SD Median Range 
IGF-I 174 * 98 140 25-496 -0.57 + 1.03 -0.55 -3.34-+1.63 <O.OOl 
IGF-II 489 + 120 479 166-777 -1.06 + 1.15 -0.8 -4.48-+1.13 <O.OOl 
IGFBP-1 30.6 t 16.7 25 14-98 -0.15 t 0.57 -0.23 -1.27-+1.62 NS 
IGFBP-2 381 k 141 356 166-689 0.27 -t- 1.49 0.38 -2.4-+3.34 NS 
IGFBP-3 3868 2 882 3964 1302-5772 1.12 t 0.98 1.28 -2.24-+2.61 <O.OOl 
a The P values refer to the difference between the patients and the control group, calculated on the basis of SDS. 
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TABLE 3. Serum levels and SDS of IGF-I, IGF-II, IGFBP-1, IGBBP-2, and IGFBP-3 in seven untreated patients with IDDM 
Serum levels (/Lg/L) SDS 
Mean +- so Median Range Mean t SD Median Range 
IGF-I 15 k 41 78 24-139 -3.68 k 2.41 -2.9 -7.6--0.55 
IGF-II 443 +- 185 439 184-654 -2.09 k 2.5 - 1.97 -6.81-+0.35 
IGFBP-1 36.1 5 17.5 34 14-72 0.15 i 0.59 1.4 -0.54-+1.3 
IGFBP-2 732 k 737 437.5 240-2357 2.34 k 3.47 1.77 -1.42-+&g 
IGFBP-3 2761 ? 13282 2751 828-4609 -1.20 2 2.99 -0.78 -7.03-+2.01 
a The P values refer to the difference between the patients and the control group, calculated on the basis of SDS. 
P 
<O.Ol 
co.01 
NS 
NS 
NS 
sooIGF-l tug/L) 
IA 
,ooolGF-lI (us/L) 
/B 
Age (YssrS) Age (years) 
03 
100 
03 
0’ J 0’ 
/ 
0 5 10 15 20 25 0 5 10 15 20 25 
Age (years) Age (years) 
81GFBP-3 (mg/L) 
IE 
0’ I 
o 5 IO 15 20 25 
Age (years) 
FIG. 1. Serum levels of IGF-I, IGF-II, IGFBP-1, IGFBP-2, and IG- 
FBP-3 in 58 patients with IDDM. The plots depict IGF-I (a), IGF-II 
(b), IGFBP-1 (c), IGFBP-2 (d), and IGFBP-3 (e) levels according to age 
(in years). The lines give the 5th, 5Oth, and 95th percentiles. Symbols 
are for individual patients: stars, untreated patients; boxes, treated 
patients. 
TABLE 4. Correlations between the SDS of IGF-I, IGF-II, 
IGFBP-1, IGFBP-2, IGFBP-3, and clinical parameters as evaluated 
by simple regression analysis 
constant Variable 
All patients 
(n = 58) 
Treated 
patients 
(n = 51) 
r P 1 P 
IGF-I SDS HbAlc (%) -0.46 <O.OOOl 
IGF-II SDS Age (yr) 0.34 co.01 
IGFBP-1 SDS Age (yr) 0.43 <O.OOl 
IGFBP-1 SDS Duration (yr) 0.37 <0.005 0.31 co.03 
IGFBP-1 SDS HbAlc (%) 0.46 <O.OOOl 0.32 co.03 
IGFBP-2 SDS HbAlc (%) 0.38 <0.003 0.3 co.04 
IGFBP-3 SDS Age (yr) 0.36 CO.01 
Only significant correlations (P < 0.05) are depicted. 
also stimulate IGF-I secretion (50-52). Thus, the puberty- 
associated increment of sex hormone serum concentrations 
could lead to the normalization of lowered IGF-I concentra- 
tions during puberty. Since diabetes may result in delayed 
puberty, it is plausible that IGF-I levels that are lower in 
diabetic children than in controls would be normal when 
adjusted for pubertal stage rather than for age. However, no 
obvious pubertal delay was present in our patients. 
Several investigators reported a significant increase of 
IGF-I levels on improvement of metabolic control in children 
and adolescents with IDDM (5,6,40,44,47,53). These data 
suggest a possible effect of glycemic control on IGF-I serum 
levels (40, 47). Indeed, we could demonstrate a significant 
inverse correlation between HbAlc and SDS IGF-I in our 
study population. In addition, in five of our patients serial 
IGF measurements could be performed over a 2-yr period: 
although the number of patients was too small to allow for 
mathematical calculations, IGF-I SDS scores rose when met- 
abolic control improved in three patients; in one patient IGF-I 
serum levels remained constant despite improved metabolic 
control, and in one patient both IGF-I SDS and HbAlc re- 
mained stable (data not shown). These findings, along with 
the data from other studies (5, 6, 39, 40, 44, 47, 531, suggest 
a possible effect of glycemic control on IGF-I levels in poorly 
controlled diabetic children. 
Since IGF-I plays a major role in growth regulation, we 
were interested in the relationship between height and IGF-I 
values. We found a strong association between height SDS 
and IGF-I SDS in prepubertal patients but not in pubertal 
patients. This is in agreement with a study from Dacou- 
Voutetakis et al. (54), who found no significant correlation of 
IGF-I levels with height SDS in healthy pubertal subjects. In 
healthy children and adolescents, a steeper regression line 
between IGF-I and GH secretory capacity is found during 
puberty than before sexual maturation. As in our diabetic 
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HbAlc (Oh) 
FIG. 2. Relationship between HbAlc and SDS IGF-I and HbAlc and 
SDS IGFBP-2 in 58 patients with IDDM (SDS IGF-I us. HbAlc, 
r = -0.46; P < 0.0001; SDS IGFBP-2 us. HbAlc, r = 0.38; P < 0.003). 
patients, IGF-I was highly correlated with height SDS in 
prepubertal healthy children (37). Thus, IGF-I and height 
SDS show a significant correlation in patients with IDDM 
similar to the correlation that exists in healthy children and 
adolescents. 
Little data exist regarding the influence of IDDM on IGF-II 
serum levels. Normal IGF-II values have been reported in 
small series of diabetic adults (5) and adolescents (39). Nev- 
ertheless, in the study of Amiel et al. (391, four patients with 
very low serum IGF-I also had depressed IGF-II levels, which 
were normalized with improved metabolic control. We 
found a significant reduction of IGF-II levels in treated as 
well as in untreated IDDM patients. 
Since IGFBP-1 seems to be the only component of the 
TABLE 5. Correlations between the SDS of IGF-I, IGF-II, 
IGFBP-1, IGFBP-2, IGFBP-3, and clinical parameters as evaluated 
by multiple regression analysis 
All patients Treated patients 
constant Variable (n = 58) (n = 51) 
F I‘ P F r P 
IGF-I SDS HbAlc (%) 5 0.46 <O.OOOl 
IGF-I SDS Height SDS 5 0.47 co.004 
IGF-II SDS Height SDS 4.5 0.43 <0.008 
IGFBP-3 SDS Height SDS 5 0.53 <O.OOl 
IGFBP-1 SDS Duration (yr) 5.4 0.51 co.04 
IGFBP-1 SDS HbAlc (%) 5.8 0.37 <O.OOl 
IGFBP-2 SDS HbAlc (%) 2.7 0.38 CO.02 1.5 0.29 co.03 
Only parameters with significant correlations in the simple 
regression model are included in the analysis. 
IGF-IGFBP system that is directly regulated by insulin, its 
pathophysiological role in diabetes is an area of intense 
investigation. When considering only studies with adequate 
age-matching or age-corresponding reference values, a sig- 
nificant increase of serum IGFBP-1 in adults and adolescents 
with IDDM is reported consistently (27,28,33,48,55,56). In 
contrast, we did not find any significant alteration of IGFBP-1 
levels in our patients. The reason for this discrepancy is not 
clear. 
Although mean HbAlc values of our patients were much 
lower than those reported in most previous studies, differ- 
ences in glycemic control cannot explain our unexpected 
findings, since we could not demonstrate markedly elevated 
serum IGFBP-1 levels even in patients with newly diagnosed, 
untreated IDDM. The serum samples of our study and con- 
trol populations were collected under nonstandardized con- 
ditions. An optimal study design had to take into account 
that IGFBP-1 levels vary depending on daytime and food 
intake. However, substantial fluctuations of serum IGFBP-1 
are mainly demonstrable during the night, whereas the vari- 
ations during daytime and after meals are rather small (56). 
The age-adjusted IGFBP-1 values of our treated patients were 
positively related to the duration of IDDM. Since the mean 
diabetes duration was rather short (4.5 yr), a longer diabetes 
duration in other study populations could provide an ex- 
planation for the higher IGFBP-1 values reported in the lit- 
erature. Despite the normal IGFBP-1 levels, we found a sig- 
nificant inverse relationship between SDS IGFBP-1 and 
HbAlc. This finding is in accordance with previous studies 
(33,48,57). The association between elevated IGFBP-1 levels 
and IGF-I inhibitory activity on cartilage sulfation in poorly 
controlled diabetic adolescents has led to the suggestion that 
IGFBP-1 may play a role in diabetes-related growth impair- 
ment (58). However, our study failed to demonstrate a sig- 
nificant relationship between height SDS and IGFBP-1 SDS. 
In agreement with the literature (48), our study demon- 
strated a complete abolition of the normal age dependence 
of IGFBP-1 levels in diabetic patients. This finding is not 
surprising, since the physiological decrease of serum IG- 
FBP-1 during childhood and puberty results from increasing 
insulin secretion. In our study population the insulin dose 
per kilogram did not differ between prepubertal and pubertal 
patients. 
In the group of insulin-treated patients, serum IGFBP-2 
was normal in pubertal and elevated in prepubertal subjects 
(P > 0.01). Comparison of patients with and without therapy 
revealed significantly higher IGFBP-2 levels in the untreated 
subjects. Interestingly, IGFBP-2 SDS was positively related to 
HbAlc. This finding would be consistent with a direct or 
indirect regulation of IGFBP-2 by insulin, analogous to the 
insulin dependence of IGFBP-1, a hypothesis that is sup- 
ported by results from animal experiments (21). In contrast, 
dynamic studies in man rather point to a role of free IGF-I (23) 
or IGF-II (11, 12, 23, 29) as a major regulator of circulating 
IGFBP-2. Although IGFBP-3 is not involved in glucose ho- 
meostasis, marked alterations of IGFBP3 levels have been 
demonstrated in patients with IDDM. Baxter et al. (59) re- 
ported a 40% reduction of serum IGFBP3 in 10 adults with 
insufficient metabolic control. Other studies revealed de- 
creased IGFBP3 levels in diabetic adolescents (42, 48). In 
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contrast, we found a significant elevation of serum IGFBP-3 
in our treated, fairly well controlled patients. Only the 7 
subjects without insulin therapy had a tendency toward re- 
duced IGFBP-3 levels. Although these data could point to an 
influence of glycemic control on IGFBP-3 levels, no relation- 
ship between HbAlc and IGFBP-3 SDS was found. In con- 
trast to the data of Batch et al. (48) and in agreement with the 
findings in Dunger et al.‘s study population (42) and in 
healthy subjects, our study revealed a positive relationship 
between IGFBP-3 levels and chronological age. A strong 
positive correlation between IGF-I and IGFBP-3 (data not 
shown) was present both in healthy subjects (37) and in 
IDDM patients. 
It is unclear which of the alterations of the IGF-IGFBP axis 
that are found in diabetes patients are of clinical significance. 
Although the influence of iuvenile-onset IDDM on adult 
height is controversial, most data indicate a negative effect 
of diabetes on linear growth (60,611. Intensification of insulin 
treatment resulting in decreased HbAlc values is not only 
associated with a significant increase in serum IGF-I, but also 
with a marked acceleration of growth velocity (6,53). In our 
study, mean height SDS was within the normal range. Nev- 
ertheless, we found a strong correlation between height SDS 
and the SDS of IGF-I, IGF-II, and IGFBP-3 in prepubertal 
patients with a diabetes duration of more than 2 yr. No such 
correlation existed in adolescents. This finding suggests that 
circulating IGF-I may be a major determinant of linear 
growth in young diabetics only during childhood, but not 
during puberty, where other factors such as sex hormones 
may play a more important role. The decrease in IGF-I levels 
seems to be even more marked when freely available IGF-I 
is considered: since IGF-I levels are low and IGFBP-3 levels 
elevated in IDDM, the IGF-I-to-IGFBP-3 ratio is markedly 
reduced. It is tempting to speculate that poor metabolic con- 
trol may impair linear growth of diabetic children at least 
partially via depression of circulating IGF-I levels and the 
alteration of IGFBP serum concentrations. The question 
whether such changes of IGF and IGFBP levels during child- 
hood and adolescence also might contribute to the develop- 
ment of late diabetic complications needs to be addressed in 
the future. 
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